Halozyme Therapeutics, announced that it has been added to the U.S. large-cap Russell 1000 Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution.

The Russell 1000 Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks.

Health Technology Insights: CVS Health Opens New Workforce Innovation and Talent Center in Chicago

“Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth,” said Dr. Helen Torley, President and CEO of Halozyme. “The inclusion will help to expand our visibility among the investment community as we continue to execute our strategy and deliver sustainable growth and profitability well into the future.”

Health Technology Insights: Colorado Access, Innovaccer Partner to Improve Medicaid Health

The Russell 1000 is managed by FTSE Russell, a global leader in index and analytics. Membership in the Russell 1000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index.

Health Technology Insights: Avio Health Launches Functional Medicine for Emagene Life

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – PR Newswire